Related Experiment Video
Updated: Jun 10, 2025

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
Published on: October 12, 2012
The Effects of Removing the Requirement for Prior Reimbursement Approval on Anticoagulant Use in Ireland: A
M Scannell1, E Burton1, P M Kearney1
1School of Public Health, University College Cork, Cork, Ireland.
Insights
Prior approval for direct oral anticoagulants (DOACs) in Ireland had minimal impact on prescribing trends. Removing this cost containment policy did not significantly alter the overall use of oral anticoagulants.
Area of Science:
- Health Economics
- Pharmacoeconomics
- Public Health Policy
Background:
- Prior approval for medication reimbursement is a cost containment strategy.
- Ireland implemented prior approval for direct oral anticoagulants (DOACs) due to financial pressures from the shift from warfarin.
- Limited studies exist on the effectiveness of prior approval policies for DOACs.
Purpose of the Study:
- To evaluate the effectiveness of prior approval for reimbursement of apixaban and rivaroxaban as a cost containment measure in Ireland.
- To analyze the impact of prior approval policies on the prescribing patterns of oral anticoagulants.
Main Methods:
- Cross-sectional study using the Irish Health Service Executive-Primary Care Reimbursement Service database (2018-2021).
- Analysis of prescribing frequencies and costs of oral anticoagulants (apixaban, rivaroxaban, warfarin).
- Time series negative binomial regression to assess the impact of removing prior approval requirements.
Main Results:
- Overall oral anticoagulant prescribing frequency increased by nearly 20% between 2018 and 2021.
- Significant variations in oral anticoagulant prescribing proportions were observed across Community Drug Schemes.
- A statistically significant decrease in apixaban use (<1%) was noted after prior approval removal.
Conclusions:
- Removal of prior approval for DOAC reimbursement in Ireland had a minimal effect on overall oral anticoagulant prescribing trends.
- Healthcare systems should carefully consider drug type, approval criteria, and policy duration when implementing prior approval policies.
- Minimizing negative effects associated with prior approval policies requires careful planning and evaluation.
Purpose:
Prior approval for reimbursement is a policy of cost containment while ensuring oversight and governance of medicines. It has been employed in Ireland to address financial challenges due to the shift from warfarin to direct oral anticoagulants (DOACs). Studies assessing the effectiveness of this policy are limited. Thus, we aimed to examine the effectiveness of prior approval for reimbursement of DOACs (apixaban, rivaroxaban) as a cost containment policy in Ireland.
Methods:
The Irish Health Service Executive-Primary Care Reimbursement Service database was used in this cross-sectional study. We examined the prescribing frequencies and associated costs of the oral anticoagulants; [(OACs) apixaban, rivaroxaban and warfarin] listed in the top 100 most frequently prescribed drugs, between 2018 and 2021. Time series negative binomial regression was used to assess the impact of removing the approval requirement of apixaban in September 2019 followed by the other DOACs in November 2020.
Results:
The prescribing frequency of OACs increased by almost 20% from 2018 to 2021. This study showed there were significant differences in the proportion of OACs prescribed among the Community Drug Schemes. A statistically significant decreased use of apixaban (< 1%, p < 0.05) occurred when prior approval was removed for all DOACs.
Conclusions:
The removal of prior approval for reimbursement of DOACs in Ireland had a minimal impact on the prescribing frequency trends of the OACs. Future use of these potentially useful policies by healthcare systems requires careful consideration of drug type, approval criteria and length of time the policy remains in place to minimise any negative effects associated with their use.
Related Concept Videos
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis III: Interprofessional Care
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Drug Regulation
Venous Thrombosis IV: Nursing Management

